Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases

Patients with inflammatory bowel diseases (IBD) have an increased risk of thrombosis, possibly due to changes in blood cells and molecules involved in hemostasis. They have increased platelet counts and reactivity as well as increased platelet-derived large extracellular vesicles. Coagulation is continuously activated in patients with IBD, based on measured markers of thrombin generation, and the anticoagulant functions of endothelial cells are damaged. Furthermore, fibrinogen is increased and fibrin clots are denser. However, pathogenesis of thrombosis in patients with IBD appears to differ from that of patients without IBD. Patients with IBD also take drugs that might contribute to riskof thrombosis, complicating the picture. We review the features of homeostasis that are altered in patients with IBD and possible mechanisms of this relationship.

Automated summary

Patients with inflammatory bowel diseases (IBD) have an increased risk of thrombosis, with reasons including increased platelet reactivity and continuous coagulation activation. Additionally, fibrinogen levels are increased and fibrin clots are denser in these patients.